Tulane Cancer Center

New Orleans, Louisiana 70112-2699

3 studies enrolling now · 28 studies all time

What they study most

Anal Cancer, Bladder Carcinoma, Brain and Central Nervous System Tumors, CLL/SLL, Castration-Resistant Prostatic Cancer, Cirrhosis, Cutaneous Melanoma, DLBCL, Diffuse Large B-cell Lymphoma, Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Esophageal Carcinoma

Studies at this site

• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer — Recruiting now
• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) — Recruiting now
• Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease — Recruiting now
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation — Recruiting now
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis — Stopped early
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL — Completed
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) — Completed
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer — Running, not enrolling
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma — Running, not enrolling
• A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma — Stopped early
• Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome — Stopped early
• Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer — Completed
• A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer — Stopped early
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL — Withdrawn before enrolling
• A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer — Completed
• Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC — Completed
• Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer — Completed
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer — Completed
• Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma — Completed
• Phase 1 of EC1169 In Patients With Recurrent MCRPC — Completed
• Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer — Completed
• S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia — Completed
• Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme — Completed
• S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer — Completed
• Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer — Completed
• PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen — Status unconfirmed